At a glance
ClinicalIndex Comparison RecordN/ACompleted· 35 enrolled
Drug / intervention
Tadalafil +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Pilot Study of Phosphodiesterase-5 Inhibitor Tadalafil (Cialis) as an Immunomodulator in Patients With Oral Cavity and Oropharyngeal Squamous Cell Carcinoma.
In Brief
A clinical study evaluating Tadalafil and Placebo for Head and Neck Cancer. Completed, enrolled 35 participants across 1 site.
Detailed Summary
RATIONALE: Biological therapies, such as tadalafil, may stimulate the immune system in different ways and stop tumor cells from growing. PURPOSE: This randomized clinical trial is studying how well tadalafil works in treating patients who are undergoing surgery for cancer of the oral cavity or oropharynx.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHead and Neck Cancer
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartSep 2008
First PostedFeb 2009
Primary CompletionApr 2015
TodayJul 2026
First PostedFeb 13, 2009
Enrollment StartSep 1, 2008
Primary CompletionApr 1, 2015
TodayJul 2, 2026
Enrollment to primary: 6.6 yearsPosted 17.4 years ago
Interventions
Tadalafildrug
Given orally
Placeboother
Given orally